Amarin Announces Results of Annual General Meeting of Shareholders

- Shareholders Approve Share Repurchase Program of up to $50 Million -

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024.

As part of the Annual General Meeting, shareholders also approved the following resolutions:

• Re-elected Mr. Patrick Holt, Mr. Louis Sterling III and Ms. Patrice Bonfiglio as directors of the Company;
• Approved the compensation of the Company’s “named executive officers” as described in full in the “Executive Compensation Discussion and Analysis” section of the Company’s definitive proxy statement;
• Approved the appointment of Ernst & Young LLP as auditors of the Company until the conclusion of the next general meeting;
• Approved the proposed amendment to the Company’s 2020 Stock Incentive Plan;
• Authorized and approved the amended and restated articles of association to require all directors to retire and seek re-election at each annual general meeting of the Company.
  

“We thank our shareholders for their engagement and for taking the time to vote on key matters for the Company,” said Odysseas Kostas, M.D. and Chairman, Amarin’s Board of Directors. “Most notably, we are pleased to have received shareholder approval to execute the planned share repurchase program which puts us one step closer to returning value to all shareholders. We look forward to completing the necessary steps to begin share repurchases as soon as possible.”

Full voting results will be included in an upcoming SEC 8-K filing.

About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.